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Background
Allergic diseases such as allergic rhinitis and bronchial 
asthma belong to the most common conditions suffered 
by children and adolescents. In many cases, the symptoms 
have a severe effect on the everyday lives of patients. Aller-
gic rhinitis is an allergic inflammation of the nasal mucosa, 
and is accompanied by itchiness, sneezing attacks, 
increased secretion of mucus, and impaired nasal breath-
ing. Frequently the condition also affects the eyes. Allergens 
ranging from pollen, fungi, epithelial animal tissue to house 
dust mites may all trigger symptoms. Bronchial asthma, in 
turn, is caused by a hypersensitivity of the bronchi to var-
ious compounds. This hypersensitivity causes reversible, 
sudden constriction of the bronchial system that leads to 
coughing, shortness of breath and wheezing. Asthma in 
the majority of children has an allergic cause [1, 2]. 
From the mid-20th century, the prevalence of allergic 
diseases in western industrialised nations saw a significant 
increase. The results of the international ISAAC study 
(International Study of Asthma and Allergies in Childhood) 
and the repeated examination of children at school-entry 
age in East and West Germany during the 1990s, revealed 
a further, albeit not so pronounced increase in Germany 
[3–5]. As far as the development over the past ten years can 
be assessed, the results from the baseline study of the 
German Health Interview and Examination Survey for Chil-
dren and Adolescents (KiGGS) between 2003 and 2006 
served as a benchmark for a comparison with the preva-
lence measured in KiGGS Wave 2 between 2014 and 2017.
Indicators and methodology
The German Health Interview and Examination Survey for 
Children and Adolescents is part of the health monitoring 
programme undertaken at the Robert Koch Institute. 
It involves repeated cross-sectional surveys of children and 
adolescents aged between 0 and 17 that are representative 
of the German population (KiGGS cross-sectional study). 
After carrying out the baseline study as an interview and 
examination survey (2003-2006) and KiGGS Wave 1 as an 
interview-based survey (2009-2012), KiGGS Wave 2 took 
place between 2014 and 2017 as a combined examination 
and interview survey. 
A detailed description of the methodology used in KiGGS 
Wave 2 can be found in New data for action. Data collection 
for KiGGS Wave 2 is completed in issue S3/2017 as well as 
KiGGS Wave 2 cross-sectional study – participant acquisi-
tion, response rates and representativeness in issue 1/2018 
of the Journal of Health Monitoring [6, 7].
On the basis of data from the KiGGS baseline study and 
KiGGS Wave 2, this article reports the trends in the 12-month 
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prevalence of allergic rhinitis and bronchial asthma in the 
group of children and adolescents aged between 3 and 17. 
In both survey waves parents were asked, whether a phy-
sician had ever diagnosed their children with the condition, 
whether the condition had occurred during the last twelve 
months and whether their child had taken any correspond-
ing medication during the last twelve months. For the group 
of children and adolescents diagnosed with allergic rhinitis 
or atopic dermatitis with a positive allergy test result, the 
survey also compared parents’ answers regarding specific 
immunotherapy between the baseline study and KiGGS 
Wave 2. 
All calculations were carried out using a weighting fac-
tor that corrects for deviations within the sample from the 
population structure with regard to age in years, gender, 
federal state, nationality and parent level of education 
(Microcensus 2013 [8]).
This article reports prevalences with 95% confidence 
intervals (95% CI). A statistically significant difference 
between groups is assumed to have been demonstrated 
with p-values of less than 0.05 (once weighting had been 
applied and the survey design had been taken into account).
Results 
Allergic rhinitis
In KiGGS Wave 2, the 12-month prevalence of physician-di-
agnosed allergic rhinitis in the 3 to 17 age group was 9.9% 
(95% CI 9.2-10.7) and has therefore remained nearly 
unchanged compared to the KiGGS baseline study (9.6%; 
95% CI 9.0-10.1). Equally unchanged are the observed cha-
rateristic differences by gender and age, with prevalence 
higher for boys than for girls (KiGGS Wave 2: 11.9% vs. 
7.9%) and a clear increase of prevalence with age for both 
genders.
Asthma
In KiGGS Wave 2, the 12-month prevalence of physician-di-
agnosed bronchial asthma in the 3 to 17 age group was 
4.0% (95% CI 3.5-4.5). Overall prevalence also has not 
changed significantly in comparison to the KiGGS baseline 
study (3.7%; 95% CI 3.3-4.1). Stratified by gender, preva-
lence among girls between the two survey points remained 
unchanged (3.0% vs. 3.1%) and increased slightly for boys 
(5.0% vs. 4.2%). This increase in prevalence is owed main-
ly to increases in the groups of boys aged 7 to 10 (5.7% vs. 
4.1%) and 11 to 13 (7.1% vs. 5.7%). 
Specific immunotherapy
The proportion of children and adolescents who have been 
medically diagnosed with allergic rhinitis or atopic derma-
titis including a positive allergy test result  and subsequent 
specific immunotherapy has increased significantly in the 
11 to 17 age group. During the KiGGS baseline study 24.3% 
(95% CI 21.3-27.6) of elder children and adolescents report-
ed having undergone a specific immunotherapy treatment, 
in KiGGS Wave 2 this proportion had increased to 30.1% 
(95% CI 26.5-33.9). 
Discussion
For both allergic rhinitis and bronchial asthma, KiGGS 
Wave 2 results, when compared to the KiGGS baseline 
study, show that following the secular trends with a signif-
icant increase in the number of cases registered during the 
second half of the 20th century, there are strong indications 
KiGGS Wave 2 
Second follow-up to the German Health 
Interview and Examination Survey for Children 
and Adolescents 
Data owner: Robert Koch Institute 
Aim: Providing reliable information on health 
status, health-related behaviour, living condi-
tions, protective and risk factors, and health 
care among children, adolescents and young 
adults living in Germany, with the possibility 
of trend and longitudinal analyses 
Study design: Combined cross-sectional and 
cohort study 
Cross-sectional study in KiGGS Wave 2
Age range: 0 -17 years
Population: Children and adolescents with 
permanent residence in Germany
Sampling: Samples from official residency 
registries - randomly selected children and  
adolescents from the 167 cities and municipal-
ities covered by the KiGGS baseline study
Sample size: 15,023 participants 
KiGGS cohort study in KiGGS Wave 2
Age range: 10 -31 years
Sampling: Re-invitation of everyone who took 
part in the KiGGS baseline study and who 
was willing to participate in a follow-up 
Sample size: 10,853 participants  
KiGGS survey waves
▶  KiGGS baseline study (2003-2006),  
examination and interview survey
▶  KiGGS Wave 1 (2009-2012),  
interview survey
▶  KiGGS Wave 2 (2014-2017),  
examination and interview survey
More information is available at 
www.kiggs-studie.de/english
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of a stabilisation of this trend, albeit at a high level. Strat-
ified by gender, the results indicate that the trends for girls 
and boys might be developing differently, particularly 
regarding bronchial asthma. Whereas the survey observed 
no changes in 12-month prevalence among girls between 
KiGGS baseline and KiGGS Wave 2, there has been a slight 
increase of prevalence for boys aged 7 to 13. The new results, 
however, give little reason for contentedness: allergic rhi-
nitis still affects over one million children and adolescents 
aged between 3 and 17, and nearly half a million suffer from 
asthma.
The increase in the number of cases receiving specific 
immunotherapy treatment as the single causal therapy for 
elder children with allergic rhinitis or atopic dermatitis is 
positive. The guidelines developed jointly by the German 
Society for Allergology and Clinical Immunology (DGAKI) 
and other allergy associations on specific immunotherapy 
to treat allergic diseases recommend an early onset of ther-
apy in particular at child and adolescent age [9] to reduce 
the risks for new sensitisation and asthma. Overall, early 
diagnosis and adequate care provision for allergic diseases 
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